Jessica Miciak is an Analyst at Catalio Capital Management L.P.
Her technical expertise is in the field of oncology and CRISPR/Cas9 gene editing, having developed unique cellular models and recombinant viruses to probe the host-viral response and tumorigenesis.
Jessica earned a B.S. and M.S. in Molecular and Cellular Biology from Johns Hopkins University and a Ph.D. in Cellular and Molecular Medicine from the Johns Hopkins School of Medicine.